Zacks: Analysts Expect Compugen Ltd. (NASDAQ:CGEN) Will Post Earnings of -$0.13 Per Share

Wall Street analysts forecast that Compugen Ltd. (NASDAQ:CGEN – Get Rating) will announce earnings of ($0.13) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Compugen’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.15). Compugen reported earnings per share of ($0.12) during the same quarter last year, which would suggest a negative year over year growth rate of 8.3%. The firm is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Compugen will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.46). For the next financial year, analysts forecast that the firm will post earnings of ($0.60) per share, with EPS estimates ranging from ($0.74) to ($0.50). Zacks’ EPS averages are an average based on a survey of analysts that cover Compugen.

Compugen (NASDAQ:CGEN – Get Rating) last issued its earnings results on Thursday, February 24th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.05. During the same period last year, the business earned ($0.10) earnings per share.

A number of analysts have commented on the company. StockNews.com upgraded Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, March 29th. Zacks Investment Research raised Compugen from a “sell” rating to a “hold” rating and set a $3.50 price target for the company in a report on Tuesday, February 8th. Oppenheimer dropped their price target on Compugen from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Finally, SVB Leerink lowered their target price on Compugen from $16.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, February 25th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $11.13.

NASDAQ:CGEN traded down $0.11 during mid-day trading on Wednesday, hitting $2.78. 100,043 shares of the company’s stock traded hands, compared to its average volume of 963,585. The firm has a 50 day moving average of $3.14 and a two-hundred day moving average of $4.40. Compugen has a 12 month low of $2.54 and a 12 month high of $9.20. The firm has a market capitalization of $190.21 million, a price-to-earnings ratio of -6.87 and a beta of 2.39.

Several large investors have recently modified their holdings of CGEN. Oppenheimer & Co. Inc. bought a new stake in Compugen during the fourth quarter worth $49,000. Walleye Trading LLC acquired a new stake in Compugen in the fourth quarter valued at $55,000. Wedbush Securities Inc. acquired a new stake in Compugen in the fourth quarter valued at $58,000. Clearwater Capital Advisors LLC acquired a new stake in Compugen during the 4th quarter worth about $59,000. Finally, Bridgefront Capital LLC acquired a new stake in Compugen during the 3rd quarter worth about $61,000. Institutional investors own 57.57% of the company’s stock.

Compugen Company Profile (Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Featured Articles